PepGen Inc. Stockholders with Large Losses Should Contact Robbins LLP for Information About the Class Action Lawsuit Against PEPG

Core Viewpoint - A class action has been filed against PepGen Inc. for allegedly misleading investors regarding the effectiveness and safety of its drug candidate PGN-EDO51, which is intended for treating Duchenne muscular dystrophy [1][2]. Company Overview - PepGen Inc. is a clinical-stage biotechnology company focused on developing oligonucleotide therapeutics for severe neuromuscular and neurologic diseases [1]. Allegations - The complaint alleges that PepGen failed to disclose critical information about PGN-EDO51, including its lower effectiveness and safety compared to what was communicated to investors [2]. - It is claimed that the CONNECT2 study was either dangerous or deficient for FDA approval, leading to the likelihood of halting the study and overstating the drug's clinical, regulatory, and commercial prospects [2]. Stock Price Impact - Following a press release on January 29, 2025, which highlighted safety concerns in the CONNECT1 study and FDA issues with the CONNECT2 study, PepGen's stock price dropped by $0.40, or 21.74%, closing at $1.44 per share on January 30, 2025 [3]. - On March 4, 2025, after announcing a voluntary pause of the CONNECT2 study, the stock price fell by $0.53, or 18.86%, closing at $2.28 per share [4]. Class Action Participation - Shareholders may be eligible to participate in the class action against PepGen, with a deadline to file a motion for lead plaintiff by August 8, 2025 [5].